CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited - 0874 CFD

20.60
0.24%
Market Trading Hours* (UTC) Opens on Monday at 01:30

Mon - Fri: 01:30 - 04:00 05:00 - 08:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading сonditions
Spread 0.45
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.023404 %
Charges from full value of position ($-4.45)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.023404%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.001486 %
Charges from full value of position ($0.28)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.001486%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency HKD
Margin 5%
Stock exchange Hong Kong
Commission on trade 0%

*Information provided by Capital.com

Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd ESG Risk Ratings

High Medium Low Negligible

‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 20.65
Open* 20.6
1-Year Change* -9.85%
Day's Range* 20.55 - 20.75
52 wk Range 19.60-27.70
Average Volume (10 days) 376.65K
Average Volume (3 months) 10.58M
Market Cap 46.40B
P/E Ratio 6.96
Shares Outstanding 1.63B
Revenue 80.61B
EPS 2.86
Dividend (Yield %) 4.07932
Beta 0.67
Next Earnings Date Mar 15, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Feb 23, 2024 20.65 0.25 1.23% 20.40 20.80 20.40
Feb 22, 2024 20.65 0.60 2.99% 20.05 20.70 20.05
Feb 21, 2024 20.20 0.40 2.02% 19.80 20.55 19.80
Feb 20, 2024 19.90 -0.05 -0.25% 19.95 20.20 19.70
Feb 19, 2024 19.85 -0.05 -0.25% 19.90 20.00 19.70
Feb 16, 2024 19.90 0.45 2.31% 19.45 20.05 19.40
Feb 15, 2024 19.45 0.10 0.52% 19.35 19.50 19.15
Feb 14, 2024 19.45 0.40 2.10% 19.05 19.80 19.05
Feb 9, 2024 19.60 0.00 0.00% 19.60 19.85 19.55
Feb 8, 2024 20.00 0.20 1.01% 19.80 20.25 19.80
Feb 7, 2024 19.80 0.05 0.25% 19.75 20.05 19.75
Feb 6, 2024 19.75 0.65 3.40% 19.10 20.00 19.10
Feb 5, 2024 19.40 0.55 2.92% 18.85 19.55 18.65
Feb 2, 2024 19.10 0.00 0.00% 19.10 19.40 18.70
Feb 1, 2024 19.15 0.50 2.68% 18.65 19.35 18.65
Jan 31, 2024 18.85 -0.20 -1.05% 19.05 19.15 18.65
Jan 30, 2024 19.00 -0.55 -2.81% 19.55 19.60 19.00
Jan 29, 2024 19.75 0.05 0.25% 19.70 20.05 19.65
Jan 26, 2024 19.70 -0.05 -0.25% 19.75 20.15 19.60
Jan 25, 2024 20.05 0.55 2.82% 19.50 20.10 19.45

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Events

Time (UTC) Country Event
No events scheduled
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 70788.2 69014.1 61673.7 64951.8 42233.8
Revenue 70788.2 69014.1 61673.7 64951.8 42233.8
Cost of Revenue, Total 57516.1 55792.6 51257.3 52092.6 32224.6
Gross Profit 13272.1 13221.4 10416.4 12859.1 10009.2
Total Operating Expense 65718 64231.2 58004.2 60899.2 38399
Selling/General/Admin. Expenses, Total 7890.66 7903.36 6329.89 8361.46 6871.99
Research & Development 777.95 837.424 577.059 543.369 558.362
Depreciation / Amortization 587.366 528.648 498.554 443.573 213.317
Interest Expense (Income) - Net Operating -450.28 -528.559 -402.433 -155.76 -530.888
Other Operating Expenses, Total -591.342 -259.305 -259.994 -387.224 -1057.67
Operating Income 5070.2 4782.84 3669.53 4052.58 3834.81
Gain (Loss) on Sale of Assets
Other, Net -26.9531 -59.7689 69.5507 75.9566 183.919
Net Income Before Taxes 5043.24 4723.07 3739.08 4128.53 4018.73
Net Income After Taxes 4253.37 3968.99 3091.63 3441.29 3533.72
Minority Interest -286.848 -249.108 -176.383 -252.403 -92.7361
Net Income Before Extra. Items 3966.52 3719.88 2915.24 3188.88 3440.98
Net Income 3966.52 3719.88 2915.24 3188.88 3440.98
Income Available to Common Excl. Extra. Items 3966.52 3719.88 2915.24 3188.88 3440.98
Income Available to Common Incl. Extra. Items 3966.52 3719.88 2915.24 3188.88 3440.98
Diluted Net Income 3966.52 3719.88 2915.24 3188.88 3440.98
Diluted Weighted Average Shares 1625.79 1625.79 1625.79 1625.79 1625.79
Diluted EPS Excluding Extraordinary Items 2.43975 2.28804 1.79312 1.96144 2.1165
Dividends per Share - Common Stock Primary Issue 0.424
Diluted Normalized EPS 2.43328 2.26582 1.79507 1.96792 2.18103
Unusual Expense (Income) -12.4733 -42.9874 3.82206 1.13955 119.322
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 18341.8 21628.5 15982.2 17585.5 16681.9
Revenue 18341.8 21628.5 15982.2 17585.5 16681.9
Cost of Revenue, Total 15125.7 16693.6 13613.8 14519.9 13871.7
Gross Profit 3216.09 4934.89 2368.49 3065.59 2810.21
Total Operating Expense 17161.3 19275.8 15369.1 16456.2 15612.8
Selling/General/Admin. Expenses, Total 1993.79 2569.27 2047.28 1817.13 1853.04
Research & Development 221.184 179.39 155.068 223.067 202.439
Interest Expense (Income) - Net Operating -129.199 -130.959 -320.469 -75.7328 -11.5529
Unusual Expense (Income) -0.07601 -0.36393 0.19216 -0.32701 -0.54634
Other Operating Expenses, Total -50.1374 -35.2074 -126.687 -27.8447 -302.345
Operating Income 1180.53 2352.76 613.108 1129.3 1069.18
Other, Net -2.82522 2.22754 -26.817 -4.5779 -0.72949
Net Income Before Taxes 1177.7 2354.99 586.291 1124.72 1068.45
Net Income After Taxes 952.688 1969.05 568.638 935.801 857.386
Minority Interest -50.0405 -60.4545 -76.4824 -51.43 -73.0305
Net Income Before Extra. Items 902.648 1908.6 492.155 884.371 784.355
Net Income 902.648 1908.6 492.155 884.371 784.355
Income Available to Common Excl. Extra. Items 902.648 1908.6 492.155 884.371 784.355
Income Available to Common Incl. Extra. Items 902.648 1908.6 492.155 884.371 784.355
Diluted Net Income 902.648 1908.6 492.155 884.371 784.355
Diluted Weighted Average Shares 1625.79 1625.79 1625.79 1625.79 1625.79
Diluted EPS Excluding Extraordinary Items 0.55521 1.17395 0.30272 0.54396 0.48245
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS 0.55517 1.17376 0.30283 0.5438 0.48218
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 57064.3 52810.6 47396.6 45982.2 43031.3
Cash and Short Term Investments 22978.6 21013.4 17819.1 18511.1 17656.9
Cash 20804.7 20946 17739 16830.5 15050.1
Cash & Equivalents 67.3176 26.1768 1639.12 1064.79
Short Term Investments 2173.89 0 54 41.4952 1542.04
Total Receivables, Net 20652.4 19174.8 17015.3 17216.1 15228.7
Accounts Receivable - Trade, Net 14857.6 12816.5 12389.7 12555 10872.5
Total Inventory 10671.6 10437.7 9764.53 9490.04 9231.74
Prepaid Expenses 915.591 794.173 1081.67 744.1 888.793
Other Current Assets, Total 1846.19 1390.46 1716 20.8704 25.1713
Total Assets 74665.3 66117.8 59760.1 56893.7 51482.2
Property/Plant/Equipment, Total - Net 6570.12 5835.88 5260.4 4726.1 3646.05
Property/Plant/Equipment, Total - Gross 11233.9 9994.76 9083.66 8145.45 6628.1
Accumulated Depreciation, Total -4663.78 -4158.88 -3823.25 -3419.34 -2982.05
Goodwill, Net 829.473 829.473 825.573 825.573 825.573
Intangibles, Net 2825.77 2592.96 2450.32 2487.3 1013.35
Long Term Investments 6103.66 3105.27 2963.83 2161.67 2299.88
Other Long Term Assets, Total 1271.97 943.637 863.312 710.777 666.04
Total Current Liabilities 37395.1 32253.9 29243.2 29377 26948.8
Accounts Payable 11200.3 11287.2 10874.8 9698.95 9313.28
Accrued Expenses 2660.45 1361.47 1083.4 1544.84 1406.38
Notes Payable/Short Term Debt 12928.8 11905.5 11550.3 9851.43 8561.88
Other Current Liabilities, Total 9898.82 7453.94 5498.64 8052.37 7463.2
Total Liabilities 42600.2 37055.6 33615.2 32708.9 29797.3
Total Long Term Debt 2185.05 1250.51 1059.37 551.495 521.738
Long Term Debt 1639.2 752.812 497.55 4.5 413.554
Deferred Income Tax 394.588 331.728 286.359 266.909 249.762
Minority Interest 1572.73 2264.48 2060.42 1804.69 1458.82
Other Liabilities, Total 1052.69 955.032 965.831 708.803 618.187
Total Equity 32065.1 29062.2 26144.8 24184.8 21684.9
Common Stock 1625.79 1625.79 1625.79 1625.79 1625.79
Additional Paid-In Capital 10105.7 9956.95 9885.01 9865.08 9865.08
Retained Earnings (Accumulated Deficit) 20346.5 17496.9 14651.7 12694.1 10194.5
Other Equity, Total 2.75475 -17.4764 -17.6735 -0.13896 -0.47714
Total Liabilities & Shareholders’ Equity 74665.3 66117.8 59760.1 56893.7 51482.2
Total Common Shares Outstanding 1625.79 1625.79 1625.79 1625.79 1625.79
Current Port. of LT Debt/Capital Leases 706.732 245.803 236.107 229.361 204.024
Capital Lease Obligations 545.843 497.698 561.824 546.995 108.185
Unrealized Gain (Loss) -15.6557
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 52925 53820.2 55437.2 57064.3 52858.4
Cash and Short Term Investments 19930.8 21088.2 20302.8 22978.6 21723.7
Cash & Equivalents
Short Term Investments 56.8727 1300.68 56.8727 2173.89 50.6686
Total Receivables, Net 21167.3 21887.3 23040.9 20652.4 20005.4
Accounts Receivable - Trade, Net 16521.8 16102.5 15951.4 14857.6 15161.5
Total Inventory 9657.39 9162.56 8945.1 10671.6 8439.79
Prepaid Expenses 857.654 579.163 503.399 915.591 620.051
Other Current Assets, Total 1311.82 1102.93 2644.94 1846.19 2069.55
Total Assets 74353.3 73607.2 73658.3 74665.3 69552.6
Property/Plant/Equipment, Total - Net 7029.23 6770.05 6624.77 6570.12 6045.7
Goodwill, Net 829.473 829.473 829.473 829.473 829.473
Intangibles, Net 2885.87 2885.73 2822.48 2825.77 2562.35
Long Term Investments 9097.68 7562.46 6655.58 6103.66 6082.15
Other Long Term Assets, Total 1586.1 1739.37 1288.83 1271.97 1174.5
Total Current Liabilities 32688.7 33049.3 32889 37395.1 31987
Accounts Payable 12620.6 11949.2 11090.4 11200.3 11718.2
Accrued Expenses 1140.69 2378.36 987.005 2660.45 976.886
Notes Payable/Short Term Debt 11689.1 11934.9 12075.2 12928.8 11867.2
Current Port. of LT Debt/Capital Leases 354.2 884.433 684.043 706.732 636.403
Other Current Liabilities, Total 6884.19 5902.42 8052.3 9898.82 6788.32
Total Liabilities 39693.3 39921.3 39690.5 42600.2 38123.8
Total Long Term Debt 3764.19 3491.34 3716.26 2185.05 2228.35
Long Term Debt 3133.04 2913.59 3136.58 1639.2 1751.9
Capital Lease Obligations 631.144 577.752 579.671 545.843 476.447
Deferred Income Tax 463.901 648.185 402.904 394.588 353.265
Minority Interest 1715.88 1689.13 1633.11 1572.73 2450.18
Other Liabilities, Total 1060.57 1043.41 1049.22 1052.69 1104.98
Total Equity 34660.1 33685.9 33967.8 32065.1 31428.8
Common Stock 1625.79 1625.79 1625.79 1625.79 1625.79
Additional Paid-In Capital 10105.7 10105.7 10105.7 10105.7 9957
Retained Earnings (Accumulated Deficit) 22947.7 21967.7 22255.1 20346.5 19854.4
Other Equity, Total -19.1267 8.75182 -18.7811 2.75475 -8.34349
Total Liabilities & Shareholders’ Equity 74353.3 73607.2 73658.3 74665.3 69552.6
Total Common Shares Outstanding 1625.79 1625.79 1625.79 1625.79 1625.79
Cash 19874 19787.6 20245.9 20804.7 21673
Property/Plant/Equipment, Total - Gross 11678.3 2066.42 11233.9 1752.47
Accumulated Depreciation, Total -4908.25 -4663.78
Unrealized Gain (Loss) -22.0436 -15.6557
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Cash From Operating Activities 6999.08 5673.5 585.185 5022.37 5216.89
Cash Taxes Paid -2759.33 -2873.35 -2637.89 -2998.66 -2158.12
Changes in Working Capital 6999.08 5673.5 585.185 5022.37 5216.89
Cash From Investing Activities -7253.19 -931.569 -1088.06 -1028.4 1109.72
Capital Expenditures -1383.87 -1254.92 -876.503 -2399.81 -478.617
Other Investing Cash Flow Items, Total -5869.31 323.348 -211.554 1371.42 1588.33
Cash From Financing Activities 45.9498 -1493.98 1439.38 -2231.81 -2751.34
Financing Cash Flow Items -8.90345 -396.831 -29.9475 -606.1 -410.892
Total Cash Dividends Paid -1490.54 -1266.06 -1289.91 -1045.69 -870.559
Issuance (Retirement) of Debt, Net 1545.39 168.908 2759.24 -580.025 -1469.89
Foreign Exchange Effects -0.50326 0.28283 -4.99446 -0.14847 0.80701
Net Change in Cash -208.665 3248.23 931.51 1762.01 3576.08
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Cash From Operating Activities -2838.88 6999.08 3299.47 1712.21 918.064
Cash Taxes Paid -1004.83 -2759.33 -2152.58 -1459 -816.54
Changes in Working Capital -2838.88 6999.08 3299.47 1712.21 918.064
Cash From Investing Activities -638.056 -7253.19 -5873.83 -2630.43 -429.199
Capital Expenditures -234.832 -1383.87 -898.324 -550.585 -274.643
Other Investing Cash Flow Items, Total -403.224 -5869.31 -4975.51 -2079.84 -154.556
Cash From Financing Activities 1571.44 45.9498 1291.27 1094.51 848.638
Financing Cash Flow Items 0.42527 -8.90345 387.949 863.484 -4.18243
Total Cash Dividends Paid -89.6695 -1490.54 -1398.89 -1140.22 -88.0997
Issuance (Retirement) of Debt, Net 1660.68 1545.39 2302.21 1371.25 940.92
Foreign Exchange Effects 1.79747 -0.50326 -0.8763 5.22974 -0.56164
Net Change in Cash -1903.7 -208.665 -1283.97 181.526 1336.94
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
Norges Bank Investment Management (NBIM) Sovereign Wealth Fund 16.0441 35281000 2248000 2023-05-24 LOW
LSV Asset Management Investment Advisor 6.0264 13252000 0 2022-12-31 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 3.1204 6861712 0 2023-09-30 LOW
Dimensional Fund Advisors, L.P. Investment Advisor/Hedge Fund 1.3024 2864000 -4000 2023-09-30 LOW
Goldman Sachs Asset Management, L.P. Investment Advisor 0.7405 1628323 46 2023-09-30 LOW
China Merchants Fund Management Co. Ltd. Investment Advisor 0.5576 1226193 856000 2023-06-30 MED
MOS Capital Investment Advisor/Hedge Fund 0.3929 864000 864000 2022-12-31 HIGH
Goldman Sachs Asset Management International Investment Advisor 0.2492 548000 0 2023-08-31 MED
California Public Employees' Retirement System Pension Fund 0.1965 432000 -50000 2022-06-30 LOW
Handelsbanken Kapitalförvaltning AB Investment Advisor/Hedge Fund 0.191 420000 0 2023-09-30 LOW
Focusbridge Investments Limited Investment Advisor 0.1592 350000 350000 2023-06-30 HIGH
First Trust Advisors L.P. Investment Advisor 0.1355 297995 -17065 2023-08-31 MED
Charles Schwab Investment Management, Inc. Investment Advisor 0.116 255142 -740 2023-09-30 LOW
Dimensional Fund Advisors, Ltd. Investment Advisor 0.1137 250000 6000 2023-09-30 LOW
AXA Investment Managers UK Ltd. Investment Advisor/Hedge Fund 0.1119 246000 0 2023-08-31 LOW
LähiTapiola Varainhoito Oy Investment Advisor 0.0937 206000 0 2022-03-31 LOW
BlackRock Investment Management (UK) Ltd. Investment Advisor/Hedge Fund 0.091 200000 0 2023-08-31 LOW
State Street Global Advisors (UK) Ltd. Investment Advisor/Hedge Fund 0.0877 192764 -4 2023-09-30 LOW
Russell Investments Limited Investment Advisor 0.0809 178000 0 2023-09-30 MED
HAC VermögensManagement AG Investment Advisor 0.0782 172000 -86000 2023-03-31 MED

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Guangzhou Baiyunshan Pharma Company profile

About Guangzhou Baiyunshan Phrmcl Hldgs Co Ltd

Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd i is engaged in the pharmaceutical and healthcare industry. The Company's segments are Great Southern TCM, Great Commerce, Great Health and Great Medical Care. The Company's Great South TCM includes research, development, manufacturing and sales for Chinese and western medicine, chemical raw medicine, natural drug, biological medicine and intermediates of chemical raw medicine. The Company's Great Health segment includes the research, development, manufacturing and sales of beverages, foods, health products and other products. The Company's Great Commerce segment includes wholesale, retail, import and export for western medicine, Chinese medicine and medical apparatus and instruments. The Great Medical segment is engaged in medical services, traditional Chinese medicine health preservation, modern pension and medical equipment industry.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Guangzhou Baiyunshan Phrmcl Hldgs Co Ltd revenues increased 12% to RMB69.01B. Net income increased 28% to RMB3.72B. Revenues reflect Business segment increase of 8% to RMB46.89B, Health segment increase of 38% to RMB10.87B, Foreign segment increase of 7% to RMB42.8M. Net income benefited from Change in Fair value decrease from RMB8.5M (expense) to RMB196.9M (income).

Industry: Pharmaceuticals (NEC)

荔湾区沙面北街45号
GUANGZHOU
GUANGDONG 510130
CN

Income Statement

  • Annual
  • Quarterly

News

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

UK Bank Earnings: What to expect from Lloyds, Barclays and HSBC?

UK banks will be in the spotlight in the week ahead as the European earnings season continues

16:38, 16 February 2024

Is Big Tech behind the apparent bull market rally?

While the Magnificent Seven have dominated market momentum in recent months, it’s not true that they are the sole drivers of the recent rally in equity markets.

16:05, 8 February 2024

US Earnings Week Ahead: Walt Disney, Uber, and Pepsi Co.

The last of the Magnificent Seven have reported, delivering mixed results. Meanwhile, according to FactSet, the S&P 500 is set for negative earnings growth for Q4, with estimates for the next quarter also downgraded.

16:24, 2 February 2024

Bank of England preview: will updated projections show more cuts are expected in 2024?

Markets have no doubt that the BoE will keep its rate unchanged

15:43, 31 January 2024

Meta Platforms Q4 earnings forecast to surge on solid ad revenues

Meta Platforms (META) reports its Q4 results after Wall Street’s closing bell on February 1, 2024. We preview what to expect from the results and analyse the stock’s technicals.

15:33, 31 January 2024

Federal Reserve meeting preview: strong data is making it hard to justify cutting rates

Markets expect the Fed to keep rates unchanged as strong economic data continues

11:30, 30 January 2024

People also watch

BTC/USD

51,094.70 Price
-1.200% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 106.00

XRP/USD

0.55 Price
-1.160% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.01168

US100

17,966.00 Price
-0.080% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0039%
Overnight fee time 22:00 (UTC)
Spread 1.8

Oil - Crude

76.58 Price
-2.180% 1D Chg, %
Long position overnight fee 0.0163%
Short position overnight fee -0.0382%
Overnight fee time 22:00 (UTC)
Spread 0.030

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading